6. Pharmaceutical removal at WWTPs with activated sludge and N-removal Compound (n=X1:X2) Number of WWTPs with at least one pair of samples Number of WWTPs with at least one pair of samples and at least one influent concentration that exceeds the limit of quantification
9. Activated sludge with N-removal and without N-removal Compound (n=X1:X2) Number of WWTPs with activated sludge and N-removal Number of WWTPs with activated sludge without N-removal
19. Ozone treatment of wastewater effluent O 3 Figure from ITT/WEDECO sales material with permission by Achim Reid
20. Scheme of an ozone system Figure from ITT/WEDECO sales material with permission by Achim Reid ozone generator energy (400 V) cooling water 5 - 32 °C feed gas O 3 grounded air / O 2 electrodes 5,5 kV offgas reaction tank
21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic. Improved risk identification strategies MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of pharmaceuticals. Stakeholder communication MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic. Improved risk identification strategies MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of pharmaceuticals. Stakeholder communication MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic. Improved risk identification strategies MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of pharmaceuticals. Stakeholder communication MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
21-04-11
21-04-11
EP08163303 Use of clorine dioxide for removal of estrogenic substances in wastewater .